3-Mar-2025 5:45 AM CST - Business Wire Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera Protagonist Therapeutics, Inc. (Protagonist) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first
30-Jan-2025 12:35 AM CST - Business Wire Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch Products, which delivered double-digit growth of 14.6% at CER. The company has upgraded its full year outlook for growth, reflecting strong year-to-date product performance and OPEX efficiencies, as well as revised foreign exchange assumptions. Takeda continues to adva
31-Oct-2024 11:45 PM CST - Business Wire Takeda anuncia resultados slidos no primeiro semestre do ano fiscal de 2024 e aumenta a perspectiva para o ano inteiro A Takeda (TOKYO:4502/NYSE:TAK) anunciou hoje os resultados do primeiro semestre do ano fiscal de 2024 (seis meses encerrados em 30 de setembro de 2024), com o impulso contnuo de seus Produtos de crescimento e lanamento. A empresa atualizou suas previses para o ano inteiro e diretrizes de administrao para refletir um desempenho mais forte do que o previsto no primeiro semestre (incluindo uma eroso de genricos do VYVANSE nos EUA mais branda do que o previst
31-Oct-2024 11:10 PM CST - Business Wire Takeda anuncia slidos resultados del primer semestre (S1) del ejercicio fiscal 2024 y eleva sus perspectivas para el ao completo Takeda (TOKYO:4502/NYSE:TAK) ha dado a conocer hoy los resultados del primer semestre del ao fiscal 2024 (seis meses finalizados el 30 de septiembre de 2024), con un impulso continuado en sus Productos de crecimiento y lanzamiento que favorecen el crecimiento. La empresa ha mejorado sus previsiones para todo el ao y las directrices de la direccin para reflejar unos resultados del primer semestre mejores de lo esperado (incluida una erosin de los genricos de V
31-Oct-2024 10:57 PM CST - Business Wire Takeda gibt starke Ergebnisse fr das erste Halbjahr des Geschftsjahres 2024 bekannt und erhht den Ausblick fr das Gesamtjahr Takeda ( TOKYO:4502/NYSE:TAK) gab heute die Ergebnisse fr das erste Halbjahr des Geschftsjahres 2024 (sechs Monate bis zum 30. September 2024) bekannt, wobei die anhaltende Dynamik bei den Growth & Launch Products das Wachstum vorantrieb. Das Unternehmen hat seine Prognosen fr das Gesamtjahr und die Management-Guidance nach oben korrigiert, um die besser als erwartete Leistung im ersten Halbjahr (einschlielich einer milder als erwarteten generischen Erosio
31-Oct-2024 10:46 PM CST - Business Wire Takeda annonce de solides rsultats pour le premier semestre de lexercice 2024 et revoit la hausse ses perspectives pour lensemble de lanne Takeda (TOKYO:4502/NYSE:TAK) a annonc aujourdhui ses rsultats pour le premier semestre de lexercice 2024 (six mois clos le 30 septembre 2024), avec une dynamique continue dans ses produits de croissance et de lancement qui stimulent la croissance. Lentreprise a revu la hausse ses prvisions pour lensemble de lanne et les orientations de la direction afin de reflter une performance plus forte que prvu au premier semestre (y compris une rosion gnrique
31-Oct-2024 10:36 PM CST - Business Wire Samenvatting: Takeda maakt sterke resulaten bekend voor de eerste helft van boekjaar 2024 en verhoogt de vooruitzichten voor het hele jaar Takeda (TOKYO:4502/NYSE:TAK) maakte vandaag de opbrengstresultaten bekend voor de eerste helft van boekjaar 2024 (zes maanden die afliepen op 30 september 2024), met een verdergezet momentum in haar Growth & Launch Products die de groei bevorderen. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.
31-Oct-2024 10:31 PM CST - Business Wire Riassunto: Takeda annuncia solidi risultati per il primo semestre dell'anno fiscale 2024 e aumenta le previsioni per l'intero anno Takeda (TOKYO:4502/NYSE:TAK) ha annunciato oggi i risultati degli utili per la prima met dell'anno fiscale 2024 (per il semestre conclusosi il 30 settembre 2024), con il continuo slancio dei suoi prodotti in crescita e di nuovo lancio che ne guidano la crescita. Il testo originale del presente annuncio, redatto nella lingua di partenza, la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodit del lettore e devono rinviare al test
31-Oct-2024 1:05 AM CST - Business Wire Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. The company has upgraded its full year forecasts and Management Guidance to reflect stronger than anticipated first-half performance (including milder than anticipated generic erosion of VYVANSE in the U.S.) and revised foreign exchange assumptions. T
3-Mar-2025 5:45 AM CST - Business Wire Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera Protagonist Therapeutics, Inc. (Protagonist) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first
30-Jan-2025 12:35 AM CST - Business Wire Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch Products, which delivered double-digit growth of 14.6% at CER. The company has upgraded its full year outlook for growth, reflecting strong year-to-date product performance and OPEX efficiencies, as well as revised foreign exchange assumptions. Takeda continues to adva
31-Oct-2024 11:45 PM CST - Business Wire Takeda anuncia resultados slidos no primeiro semestre do ano fiscal de 2024 e aumenta a perspectiva para o ano inteiro A Takeda (TOKYO:4502/NYSE:TAK) anunciou hoje os resultados do primeiro semestre do ano fiscal de 2024 (seis meses encerrados em 30 de setembro de 2024), com o impulso contnuo de seus Produtos de crescimento e lanamento. A empresa atualizou suas previses para o ano inteiro e diretrizes de administrao para refletir um desempenho mais forte do que o previsto no primeiro semestre (incluindo uma eroso de genricos do VYVANSE nos EUA mais branda do que o previst
31-Oct-2024 11:10 PM CST - Business Wire Takeda anuncia slidos resultados del primer semestre (S1) del ejercicio fiscal 2024 y eleva sus perspectivas para el ao completo Takeda (TOKYO:4502/NYSE:TAK) ha dado a conocer hoy los resultados del primer semestre del ao fiscal 2024 (seis meses finalizados el 30 de septiembre de 2024), con un impulso continuado en sus Productos de crecimiento y lanzamiento que favorecen el crecimiento. La empresa ha mejorado sus previsiones para todo el ao y las directrices de la direccin para reflejar unos resultados del primer semestre mejores de lo esperado (incluida una erosin de los genricos de V
31-Oct-2024 10:57 PM CST - Business Wire Takeda gibt starke Ergebnisse fr das erste Halbjahr des Geschftsjahres 2024 bekannt und erhht den Ausblick fr das Gesamtjahr Takeda ( TOKYO:4502/NYSE:TAK) gab heute die Ergebnisse fr das erste Halbjahr des Geschftsjahres 2024 (sechs Monate bis zum 30. September 2024) bekannt, wobei die anhaltende Dynamik bei den Growth & Launch Products das Wachstum vorantrieb. Das Unternehmen hat seine Prognosen fr das Gesamtjahr und die Management-Guidance nach oben korrigiert, um die besser als erwartete Leistung im ersten Halbjahr (einschlielich einer milder als erwarteten generischen Erosio
31-Oct-2024 10:46 PM CST - Business Wire Takeda annonce de solides rsultats pour le premier semestre de lexercice 2024 et revoit la hausse ses perspectives pour lensemble de lanne Takeda (TOKYO:4502/NYSE:TAK) a annonc aujourdhui ses rsultats pour le premier semestre de lexercice 2024 (six mois clos le 30 septembre 2024), avec une dynamique continue dans ses produits de croissance et de lancement qui stimulent la croissance. Lentreprise a revu la hausse ses prvisions pour lensemble de lanne et les orientations de la direction afin de reflter une performance plus forte que prvu au premier semestre (y compris une rosion gnrique
31-Oct-2024 10:36 PM CST - Business Wire Samenvatting: Takeda maakt sterke resulaten bekend voor de eerste helft van boekjaar 2024 en verhoogt de vooruitzichten voor het hele jaar Takeda (TOKYO:4502/NYSE:TAK) maakte vandaag de opbrengstresultaten bekend voor de eerste helft van boekjaar 2024 (zes maanden die afliepen op 30 september 2024), met een verdergezet momentum in haar Growth & Launch Products die de groei bevorderen. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.
31-Oct-2024 10:31 PM CST - Business Wire Riassunto: Takeda annuncia solidi risultati per il primo semestre dell'anno fiscale 2024 e aumenta le previsioni per l'intero anno Takeda (TOKYO:4502/NYSE:TAK) ha annunciato oggi i risultati degli utili per la prima met dell'anno fiscale 2024 (per il semestre conclusosi il 30 settembre 2024), con il continuo slancio dei suoi prodotti in crescita e di nuovo lancio che ne guidano la crescita. Il testo originale del presente annuncio, redatto nella lingua di partenza, la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodit del lettore e devono rinviare al test
31-Oct-2024 1:05 AM CST - Business Wire Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. The company has upgraded its full year forecasts and Management Guidance to reflect stronger than anticipated first-half performance (including milder than anticipated generic erosion of VYVANSE in the U.S.) and revised foreign exchange assumptions. T
